KPMG in Precision Medicine

Strategy | Deals | Operations

Alasdair Milton, PhD

Alasdair Milton, PhD

Managing Director, Healthcare and Life Sciences Strategy, KPMG US

+1 617-988-5419

Puja Ghelani

Puja Ghelani

Director, Healthcare and Life Sciences Strategy, KPMG US

+1 918-845-2389

Kristin C. Pothier

Kristin C. Pothier

Global & National, HCLS Deal Advisory & Strategy Leader, KPMG US

+1 617 549 2779

In the complex and fast-moving Precision Medicines market clients seek advisors who can provide deep scientific, technical and business insights at a local and global level. Part of the Healthcare and Life Sciences Strategy team, our Precision Medicine practice is a leader in this innovative area of medicine across all therapeutic areas, in markets around the world, with all relevant stakeholders and fueled by experience across the value chain. 

Precision Medicine
Navigating innovation in a new normal

The real keys to innovative deal making in Precision Medicine in 2022

Industry leaders Kristin Pothier, KPMG Global Deal Advisory and Strategy Leader for Healthcare and Life Sciences, and Bonnie Anderson, Chairwoman and former CEO of Veracyte, talk about how strategic deals transformed the company and enabled its growth to market leadership. Kristin and Bonnie discuss the end-to-end journey for successful transactions - from strategic planning, through due diligence, integration, and transformation – and offer outlooks for the year ahead.

See us in action

Watch our Precision Medicine leaders talk about the practice and how KPMG is supporting our clients in their deals, and shaping their strategic direction and operations within this innovative industry.

Who we work with


Hospital & Healthcare Systems




Diagnostic & Life
Science Tools Companies


Commercial, Academic 
& Hospital Labs


Private Investors

Our services


The foundation of Precision Medicine (PM) has evolved from the simplicity of ‘right patient, right drug, right time’ to now encompass cutting edge sequencing, diagnostic, and therapeutic technologies that are impacting clinical outcomes for patients. We help our clients solve their most complex strategic problems on a G-LOCAL level – global strategic focus and local level execution, leveraging our deep market knowledge, and powered by a proprietary database.

Case study
Defining an organizational and capabilities roadmap for future market leadership for an oncology medical affairs team in a global biopharma client
Case study
Global market assessment of the current and future Precision Medicine landscape to optimize future launch strategies for a global biopharma client
Case study
Developing the go-forward strategy for a leading diagnostics company


The Precision Medicines deal market is one of the most active and dynamic in the Life Sciences industry. Our Precision Medicines team supports clients across the deal continuum, from front-end ideation and planning, to commercial, financial and operational due diligence, and through integration and separation. Our practice has been on the buy and sell-side for deals in the Precision Medicine ecosystem for both corporate and private entities.

Case study
Assessing the commercial viability and investment thesis of an early-stage oncology diagnostics company
Case study
Identifying M&A targets for a leading diagnostics company
Case study
Assessing the commercial viability of assets across multiple indications for a royalty rights opportunity


Operating a high-performing organization in the Precision Medicine space requires enabling capabilities and functions to bridge strategy through execution, to keep pace with regulatory changes and the evolution of technology. KPMG leverages a holistic approach, helping organizations design and align operating models with business strategy, positioning the mid- and back-office functions of Precision Medicine organizations for performance transformation and commercial success.

Case Study
Current state assessment and gap analysis to design an improved market access governance model for a global biopharma
Case study
Setting up COVID-19 testing capabilities for one of the largest reference labs in the United States
Case study
Post-merger operational enablement of a genomics diagnostic acquisition